Patent intelligence · US
US 10961238
Modulators of hedgehog (Hh) signaling pathway
Modulators of hedgehog (Hh) signaling pathway
Patent details — US 10961238
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 30, 2021
- Expiration
- Mar 25, 2041
- Applicant
- E-Therapeutics PLC
- Claims
- 18
- CPC classes
- A61P, A61P35/00
Quick answer
US 10961238 (Modulators of hedgehog (Hh) signaling pathway) is held by E-Therapeutics PLC. Status: granted. Granted Mar 30, 2021. Expires Mar 25, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- E-Therapeutics PLC
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61P, A61P35/00
More from E-Therapeutics PLC
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 10961238?
US 10961238 (Modulators of hedgehog (Hh) signaling pathway) is held by E-Therapeutics PLC. Status: granted. Granted Mar 30, 2021. Expires Mar 25, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10961238?
E-Therapeutics PLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 10961238 expire?
Our index shows an expiration date of Mar 25, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.